The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate deriv
The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.
대표청구항▼
1. A method for inhibiting viral infection, comprising: administering an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof to a subject: where:R1 to R6 are each a hydrogen atom, sodium, potassium, or an acyl group and may be i
1. A method for inhibiting viral infection, comprising: administering an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof to a subject: where:R1 to R6 are each a hydrogen atom, sodium, potassium, or an acyl group and may be identical to or different from one another,the acyl group is a lauroyl group, a farnesoyl group, a linoleyl group or a linolenyl group,one of R1 to R6 is the acyl group,each of R7 to R11, R13, R15, and R16 is a hydrogen atom, andR12 and R14 are each a hydrogen atom, sodium, or potassium and may be identical to or different from one another,wherein the method inhibits viral infection by a virus having an envelope, andwherein the method inhibits viral infection by inhibiting membrane fusion. 2. The method according to claim 1, wherein one of R1, R2, R5, and R6 is the acyl group. 3. The method according to claim 1, wherein one of R1, R2, R5, and R6 is the acyl group, and the rest are each a hydrogen atom. 4. The method according to claim 1, wherein R7 to R16 are each a hydrogen atom. 5. The method according to claim 1, wherein the acyl is a linoleyl group or a linolenyl group. 6. The method according to claim 1, wherein a mixture of epigallocatechin gallate derivatives are administered, and the mixture comprises a first derivative in which R1 is the acyl group, a second derivative in which R2 is the acyl group, a third derivative in which R5 is the acyl group, and a fourth derivative in which R6 is the acyl group.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (1)
Shimamura Tadakatsu (4-4 ; Nishihara-1-chome Shibuya-ku Tokyo JPX) Hara Yukihiko (Fujieda JPX), Method for inhibiting and treating infection caused by influenza virus.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.